Stock ALACT ACTICOR BIOTECH SAS
Add to a list
To use this feature you must be a member
Log inSign up

All News Acticor Biotech SAS

Equities

ALACT

FR0014005OJ5

End-of-day quote Euronext Paris
Other stock markets
 06:00:00 2024-05-14 pm EDT 		5-day change 1st Jan Change
1.14 EUR +35.71% Intraday chart for Acticor Biotech SAS +35.71% -60.69%
May. 15 Acticor: 'new perspectives' in stroke treatment CF
May. 15 Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acticor: 'new perspectives' in stroke treatment
CF
ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
BU
Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024
CI
ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023
BU
Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results
CI
Acticor Biotech: rebound from the previous day's tumble
CF
Acticor Biotech: Phase 2/3 study fails
CF
ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment
BU
Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment
CI
Acticor Biotech: phase 2/3 results expected in May
CF
Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
BU
Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024
CI
Acticor Biotech: falls after capital increase
CF
Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development
MT
Acticor Biotech Completes a Capital Increase for a Total Gross Amount of 8 Million Euros
BU
The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack
AQ
The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack
CI
Acticor: 'we are delighted to observe the market's reaction'.
CF
Acticor Biotech continues to soar, hopes for stroke treatment
CF
Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALACT Stock
  4. News Acticor Biotech SAS
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW